|
|
Article: NICE Backs Xolair(R)-Delta for Severe, Persistent Allergic Asthma.
- Article from:
- PR Newswire Europe
- Article date:
- August 31, 2007
|
Copyright informationCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FRIMLEY, England, August 31 /PRNewswire/ --
- Clinicians Welcome Drug Watchdog's Decision to Grant NHS Patients Access to Xolair(R) (Omalizumab) for Severe, Persistent Allergic Asthma.
Novartis today welcomes the decision made by the National Institute for Health and Clinical Excellence (NICE) to recommend the use of Xolair(R) (omalizumab) in adolescents (12 years of age and above) and adults with severe, persistent allergic asthma(1). Evidence shows that, when used as add-on treatment, Xolair can significantly improve symptom contro(l2) and quality of life in those patients in whom best current management has failed.
Xolair is the first drug shown to stabilise ...
Related newspaper, magazine, and journal articles:
|